But it’s a slippery slope. When does reducing the risk of inherited breast cancer, diabetes, or Alzheimer’s disease edge into “designer baby” territory? As scientists grapple with the implications of ...

Today’s headlines highlight critical developments in genetic medicine, global politics, and the latest updates from the ...

(Designer Babies – Like it or not, Here they come ... I strongly favor a moratorium on clinical use of CRISPR in humans, and I hope that the National Academy of Sciences meeting this week comes to ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

The epigenetic state of chromatin, gene activity, and chromosomal positions are interrelated. A research team from the IPK ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day. ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

Get Instant Summarized Text (Gist) CRISPR nucleases, Cas9 and Cas12, have been engineered to evade immune detection, addressing a key challenge in CRISPR-based therapies. By identifying and ...